The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases.
The selection of a development candidate has triggered a milestone payment of EUR6.5m to Orexo.
Under agreement, Boehringer Ingelheim is responsible for all further compound development and marketing.
However, Orexo has the option to co-promote the products arising from this collaboration in the Nordic and Baltic countries.
Boehringer Ingelheim Research corporate senior vice president Wolfgang Rettig said that the medical need in the area of pain and inflammation is considerable and this collaboration has the potential to address the patients’ and physicians’ need for a new treatment regarding safety and efficacy.